{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:56Z","timestamp":1753891076708,"version":"3.41.2"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>UBA1 and UBA6 are classic ubiquitin-activating E1 enzymes, which participate in the ubiquitination degradation of intracellular proteins and are closely related to the occurrence and development of various diseases and tumors. However, at present, comprehensive analysis has not been used to study the role of UBA family in cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We extracted the relevant data of cancer patients from the TCGA database and studied the relationship between the expression patterns of UBA family and the survival rate, and stage of patients in pan-cancer, especially breast cancer (BRCA), colorectal cancer (COAD), renal cancer (KIRC) and lung adenocarcinoma (LUAD). In addition, we also evaluated their impact on immune infiltration using TISIDB database and R packages.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>UBA1 and UBA6 are highly expressed in most cancer types, which may be associated with poor prognosis of patients. This study also investigated their expression had a closely tie with clinical stages in some specific tumors. Furthermore, this study also demonstrated that these genes were closely related to immune score, immune subtypes and tumor infiltrating immune cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study demonstrated that the differential expression of the UBA family, along with their associated survival landscape and immune infiltration across various cancer types, holds potential as biomarkers linked to cancer immune infiltration. This finding offers a novel perspective for informing the direction of cancer treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1510503","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T06:47:19Z","timestamp":1739774839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-omics analysis identifies UBA family as potential pan-cancer biomarkers for tumor prognosis and immune microenvironment infiltration"],"prefix":"10.3389","volume":"16","author":[{"given":"Haibin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XinLi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3390\/cancers12040902","article-title":"Drug development targeting the ubiquitin-proteasome system (UPS) for the treatment of human cancers","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.03.008","article-title":"Dissenting degradation: Deubiquitinases in cell cycle and cancer","volume":"67","author":"Bonacci","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.706395","article-title":"E3 ubiquitin ligase-mediated regulation of osteoblast differentiation and bone formation","volume":"9","author":"Shen","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2008.12.030","article-title":"The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy","volume":"283","author":"Motegi","year":"2009","journal-title":"Cancer Lett"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4161\/cc.19978","article-title":"Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage","volume":"11","author":"Moudry","year":"2012","journal-title":"Cell Cycle"},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.imlet.2018.08.001","article-title":"Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases","volume":"202","author":"Bulatov","year":"2018","journal-title":"Immunol Lett"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.3390\/ijms22116107","article-title":"Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to TGF-\u03b2 and the ubiquitin-proteasome pathway","volume":"22","author":"Inui","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-020-01281-8","article-title":"Ubiquitin-proteasome system (UPS) as a target for anticancer treatment","volume":"43","author":"Park","year":"2020","journal-title":"Arch Pharm Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"200390","DOI":"10.1098\/rsob.200390","article-title":"Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy","volume":"11","author":"Aliabadi","year":"2021","journal-title":"Open Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.48437","article-title":"E3 Ubiquitin ligase NEDD4 family\u2212regulatory network in cardiovascular disease","volume":"16","author":"Zhang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.3390\/ijms23095053","article-title":"Ubiquitin and ubiquitin-like proteins in cancer, neurodegenerative disorders, and heart diseases","volume":"23","author":"Hwang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.3390\/ijms21113904","article-title":"Regulation of wnt signaling through ubiquitination and deubiquitination in cancers","volume":"21","author":"Park","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-060815-014922","article-title":"Ubiquitin ligases: structure, function, and regulation","volume":"86","author":"Zheng","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature05902","article-title":"Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging","volume":"447","author":"Jin","year":"2007","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1586\/era.13.9","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"13","author":"McBride","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada","year":"2022","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0344","article-title":"Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small-cell lung cancer","volume":"28","author":"Majeed","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592413","article-title":"Ubiquitin-like modifier activating enzyme 1 as a novel diagnostic and prognostic indicator that correlates with ferroptosis and the Malignant phenotypes of liver cancer cells","volume":"10","author":"Shan","year":"2020","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and Malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Obiorah","year":"2021","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231191","article-title":"The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma","volume":"115","author":"Xu","year":"2010","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41419-021-04023-w","article-title":"GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1038\/s41467-022-32040-6","article-title":"Structures of UBA6 explain its dual specificity for ubiquitin and FAT10","volume":"13","author":"Truongvan","year":"2022","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.107789","article-title":"The proteomic analysis of endogenous FAT10 substrates identifies p62\/SQSTM1 as a substrate of FAT10ylation","volume":"125","author":"Aichem","year":"2012","journal-title":"J Cell Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1038\/s41467-022-33116-z","article-title":"Inhibition of UBA6 by inosine augments tumour immunogenicity and responses","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.02.014","article-title":"Altered social behavior and neuronal development in mice lacking the Uba6-Use1 ubiquitin transfer system","volume":"50","author":"Lee","year":"2013","journal-title":"Mol Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbr.2014.12.019","article-title":"Impairment of social behavior and communication in mice lacking the Uba6-dependent ubiquitin activation system","volume":"281","author":"Lee","year":"2015","journal-title":"Behav Brain Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/cells11010105","article-title":"Ubiquitin activating enzyme UBA6 regulates th1 and tc1 cell differentiation","volume":"11","author":"Lee","year":"2021","journal-title":"Cells"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/biom10060834","article-title":"Significance of STAT3 in immune infiltration and drug response in cancer","volume":"10","author":"Chen","year":"2020","journal-title":"Biomolecules"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz210","article-title":"TISIDB: an integrated repository portal for tumor-immune system interactions","volume":"35","author":"Ru","year":"2019","journal-title":"Bioinformatics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty411","article-title":"GSCALite: a web server for gene set cancer analysis","volume":"34","author":"Liu","year":"2018","journal-title":"Bioinformatics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq537","article-title":"The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function","volume":"38","author":"Warde-Farley","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0335","article-title":"Using cellMiner 1.6 for systems pharmacology and genomic analysis of the NCI-60","volume":"21","author":"Reinhold","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"15104","DOI":"10.3390\/ijms232315104","article-title":"Progress in anticancer drug development targeting ubiquitination-related factors","volume":"23","author":"Li","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00454-5","article-title":"Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer","volume":"22","author":"Labrie","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pharmrev.120.000053","article-title":"E1 enzymes as therapeutic targets in cancer","volume":"73","author":"Barghout","year":"2021","journal-title":"Pharmacol Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3739","article-title":"Ubiquitination in disease pathogenesis and treatment","volume":"20","author":"Popovic","year":"2014","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1242\/dev.011288","article-title":"The E1 ubiquitin-activating enzyme Uba1 in Drosophila controls apoptosis autonomously and tissue growth non-autonomously","volume":"135","author":"Lee","year":"2008","journal-title":"Development"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nature07959","article-title":"Ubiquitylation in innate and adaptive immunity","volume":"458","author":"Bhoj","year":"2009","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.40","article-title":"Ubiquitin signaling in immune responses","volume":"26","author":"Hu","year":"2016","journal-title":"Cell Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2019.02.002","article-title":"Ubiquitin ligases in cancer immunotherapy - balancing antitumor and autoimmunity","volume":"25","author":"Fujita","year":"2019","journal-title":"Trends Mol Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607769103","article-title":"Impaired nucleotide excision repair upon macrophage differentiation is corrected by E1 ubiquitin-activating enzyme","volume":"103","author":"Nouspikel","year":"2006","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B45","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","article-title":"Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity","volume":"15","author":"Yan","year":"2022","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1510503\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:08:15Z","timestamp":1739959695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1510503\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2025.1510503"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1510503","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"article-number":"1510503"}}